Claims for Patent: 11,045,461

Summary for Patent: 11,045,461

Title:	Compositions of CXCR4 inhibitors and methods of preparation and use
Abstract:	The present invention provides compositions and methods of use for treating, preventing, or ameliorating a disease, disorder, or condition associated with a chemokine receptor such as CXCR4.
Inventor(s):	Brands Karel Marie Joseph
Assignee:	X4 PHARMACEUTICALS, INC.
Application Number:	US16704302
Patent Claims:	2. The X4P-001 composition of claim 1 , wherein the amount of I-6 claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , is from about 0.01 to about 0.4% w/w of the X4P-001 composition.3. The X4P-001 composition of claim 1 , wherein the amount of I-6 claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , is from about 0.01 to about 0.3% w/w of the X4P-001 composition.4. The X4P-001 composition of claim 1 , wherein the amount of I-6 is from 0.01 to 0.2% w/w of the X4P-001 composition.9. The X4P-001 composition of claim 8 , wherein the X4P-001 composition does not comprise I-2 or I-5 claim 8 , or a pharmaceutically acceptable salt thereof claim 8 , in a detectable amount.10. The X4P-001 composition of claim 5 , wherein the amount of I-2 claim 5 , or a pharmaceutically acceptable salt thereof claim 5 , is from about 0.01 to about 0.3% w/w of the X4P-001 composition.11. The X4P-001 composition of claim 6 , wherein the amount of I-3 claim 6 , or a pharmaceutically acceptable salt thereof claim 6 , is from about 0.01 to about 0.4% w/w of the X4P-001 composition.12. The X4P-001 composition of claim 8 , wherein the amount of I-3 claim 8 , or a pharmaceutically acceptable salt thereof claim 8 , is from about 0.01 to about 0.4% w/w of the X4P-001 composition.13. The X4P-001 composition of claim 7 , wherein the amount of I-5 claim 7 , or a pharmaceutically acceptable salt thereof claim 7 , is from about 0.01 to about 0.4% w/w of the X4P-001 composition.14. The X4P-001 composition of claim 12 , wherein the amount of I-7 claim 12 , or a pharmaceutically acceptable salt thereof claim 12 , is from about 0.01 to about 0.25% w/w of the X4P-001 composition.15. The X4P-001 composition of claim 14 , wherein the compound of formula I is present in the X4P-001 composition as a free base.16. The X4P-001 composition of claim 15 , wherein the composition comprises no more than 3.0% of total impurities.17. The X4P-001 composition of claim 16 , wherein the R-enantiomeric excess (% ee) of the compound of formula I is no less than 97.0%.18. The X4P-001 composition of claim 16 , wherein the total weight of I-6 and any additional impurities that are present comprise no more than about 0.8% w/w of the X4P-001 composition.19. A pharmaceutical composition comprising the X4P-001 composition according to claim 1 , and a pharmaceutically acceptable adjuvant claim 1 , carrier claim 1 , or vehicle.20. A pharmaceutical composition comprising the X4P-001 composition according to claim 15 , and a pharmaceutically acceptable adjuvant claim 15 , carrier claim 15 , or vehicle.